Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
The Lancet. Oncology
|
September 11, 2012
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
Tim Eisen, Heikki Joensuu, Paul D Nathan, et al.
Journal for Immunotherapy of Cancer
|
June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.
Molecular Cancer Therapeutics
|
October 22, 2015
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
Victoria L Bridgeman, Elaine Wan, Shane Foo, et al.
BMC Cancer
|
November 16, 2019
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
Hannah L Buckley, Fiona J Collinson, Gemma Ainsworth, et al.
The Lancet. Oncology
|
February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
Mahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
The Oncologist
|
March 22, 2015
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors
Chooi Peng Lee, N Jane Taylor, Gerhardt Attard, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
The Lancet. Oncology
|
April 22, 2014
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
Pippa G Corrie, Andrea Marshall, Janet A Dunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2013
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
Antoni Ribas, Richard Kefford, Margaret A Marshall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Jan C Brase, Robert F H Walter, Alexander Savchenko, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
The Lancet. Oncology
|
September 11, 2012
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
Tim Eisen, Heikki Joensuu, Paul D Nathan, et al.
Journal for Immunotherapy of Cancer
|
June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.
Molecular Cancer Therapeutics
|
October 22, 2015
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
Victoria L Bridgeman, Elaine Wan, Shane Foo, et al.
BMC Cancer
|
November 16, 2019
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
Hannah L Buckley, Fiona J Collinson, Gemma Ainsworth, et al.
The Lancet. Oncology
|
February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
Mahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
The Oncologist
|
March 22, 2015
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors
Chooi Peng Lee, N Jane Taylor, Gerhardt Attard, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
The Lancet. Oncology
|
April 22, 2014
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
Pippa G Corrie, Andrea Marshall, Janet A Dunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2013
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
Antoni Ribas, Richard Kefford, Margaret A Marshall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Jan C Brase, Robert F H Walter, Alexander Savchenko, et al.
Page
of 3